Advanced Liver Cancer Clinical Trial
Official title:
Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for liver cancer.
Liver cancer is one of the most common malignancies in China, ranking fourth in all malignant tumors and third in mortality. Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single-center, randomized (1:1of targeted activation CIK and traditional CIK therapy )comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. The investigators plan to recruit for 80 cases patients with advanced liver cancer, the first 20 cases were directly received treatment of activated CIK, and the cases after the 20th were randomly assigned to two group，one of the two group will receive treatment of traditional CIK, and the other receive activated CIK. The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01754987 -
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05698459 -
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer
|
Phase 1 | |
| Withdrawn |
NCT03484962 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT05603039 -
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04906434 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04163237 -
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
|
Phase 3 | |
| Recruiting |
NCT02862613 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02873442 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03474822 -
Plasmodium Immunotherapy for Breast and Liver Cancers
|
Phase 1/Phase 2 |